125 related articles for article (PubMed ID: 21350107)
1. Fixation time does not affect expression of HER2/neu.
Goldsmith JD; Allred DC; Beasley MB; Eisen R; Fulton RS; Gown AM; Hammond ME
Am J Clin Pathol; 2011 Mar; 135(3):484; author reply 485. PubMed ID: 21350107
[No Abstract] [Full Text] [Related]
2. Fixation time does not affect expression of HER2/neu: a pilot study.
Ibarra JA; Rogers LW
Am J Clin Pathol; 2010 Oct; 134(4):594-6. PubMed ID: 20855640
[TBL] [Abstract][Full Text] [Related]
3. Fixation time and HER2/neu assessment.
Bohn OL; Sanchez-Sosa S; Ibarra JA; Rogers LW
Am J Clin Pathol; 2011 Jun; 135(6):979-80; author reply 980. PubMed ID: 21571969
[No Abstract] [Full Text] [Related]
4. Fixation time does not affect the expression of estrogen receptor.
Ibarra JA; Rogers LW; Kyshtoobayeva A; Bloom K
Am J Clin Pathol; 2010 May; 133(5):747-55. PubMed ID: 20395521
[TBL] [Abstract][Full Text] [Related]
5. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.
Moatamed NA; Nanjangud G; Pucci R; Lowe A; Shintaku IP; Shapourifar-Tehrani S; Rao N; Lu DY; Apple SK
Am J Clin Pathol; 2011 Nov; 136(5):754-61. PubMed ID: 22031314
[TBL] [Abstract][Full Text] [Related]
6. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
Yildiz-Aktas IZ; Dabbs DJ; Cooper KL; Chivukula M; McManus K; Bhargava R
Am J Clin Pathol; 2012 May; 137(5):691-8. PubMed ID: 22523206
[TBL] [Abstract][Full Text] [Related]
7. Protein and gene expression of estrogen receptor alpha and nuclear morphology of two breast cancer cell lines after different fixation methods.
Nykänen M; Kuopio T
Exp Mol Pathol; 2010 Apr; 88(2):265-71. PubMed ID: 20025868
[TBL] [Abstract][Full Text] [Related]
8. Automated analysis of FISH-stained HER2/neu samples with Metafer.
Schunck C; Mohammad E
Methods Mol Biol; 2011; 724():91-103. PubMed ID: 21370008
[TBL] [Abstract][Full Text] [Related]
9. Effect of prolonged formalin fixation on immunohistochemical staining for the proliferation marker Ki67.
Hitchman E; Hodgkinson C; Roberts D; Ashton G; Yunus Z; Byers R; Ward T; Womack C; Dive C
Histopathology; 2011 Dec; 59(6):1261-3. PubMed ID: 21939458
[No Abstract] [Full Text] [Related]
10. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
[TBL] [Abstract][Full Text] [Related]
11. Her2/neu analysis in formalin-fixed, paraffin-embedded breast carcinomas: comparison of immunohistochemistry and multiparameter DNA flow cytometry.
Leers MP; Hoop JG; Nap M
Anticancer Res; 2003; 23(2A):999-1006. PubMed ID: 12820338
[TBL] [Abstract][Full Text] [Related]
12. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
Mueller RE; Parkes RK; Andrulis I; O'Malley FP
Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
[TBL] [Abstract][Full Text] [Related]
13. The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium.
Ratcliffe N; Wells W; Wheeler K; Memoli V
Mod Pathol; 1997 Dec; 10(12):1247-52. PubMed ID: 9436971
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
15. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer.
Mitchell MS; Press MF
Semin Oncol; 1999 Aug; 26(4 Suppl 12):108-16. PubMed ID: 10482202
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.
Beatty BG; Bryant R; Wang W; Ashikaga T; Gibson PC; Leiman G; Weaver DL
Am J Clin Pathol; 2004 Aug; 122(2):246-55. PubMed ID: 15323142
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
[TBL] [Abstract][Full Text] [Related]
18. Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma.
Selvarajan S; Bay BH; Choo A; Chuah KL; Sivaswaren CR; Tien SL; Wong CY; Tan PH
J Histochem Cytochem; 2002 Dec; 50(12):1693-6. PubMed ID: 12486093
[TBL] [Abstract][Full Text] [Related]
19. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
[TBL] [Abstract][Full Text] [Related]
20. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
